Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome
Rituximab (RTX) is a promising option for treating childhood-onset steroid-dependent (SDNS), frequently relapsing (FRNS), and steroid-resistant (SRNS) nephrotic syndrome.
We retrospectively surveyed RTX treatment for these conditions to evaluate its indications, efficacy and adverse events. Questionnaires were sent to 141 hospitals in Japan.
Seventy-four patients (52 SDNS; 3 FRNS; 19 SRNS) were treated with RTX because of resistance to various immunosuppressive agents. Most patients received a single administration of RTX (85%). Forty-one of 53 SDNS/FRNS (77%) and 5 of 17 SRNS (29%) patients successfully discontinued prednisolone (16 SDNS/FRNS and 6 SRNS achieved their first discontinuation since onset), and 17 out of 53 SDNS/FRNS patients (31%) discontinued cyclosporine. However, 28 of the 53 patients (51%) relapsed. Although immunosuppressive agents did not extend B cell depletion, relapses were significantly less if immunosuppressive agents were continued after RTX (P = 0.006; hazard ratio = 0.2). Among the SRNS patients, complete (n = 6) and partial remission (n = 6) were achieved. No life-threatening adverse events were experienced.
Although this was a multi-center survey where treatment of nephrotic syndrome varied between centers, the steroid-sparing effect of RTX in SDNS/FRNS was excellent. If single administration of RTX is chosen, continuation of immunosuppressive agents is recommended for prevention of relapse.
KeywordsRituximab Nephrotic syndrome Children Steroid Steroid-dependent nephrotic syndrome Steroid-resistant nephrotic syndrome Immunosuppressive agents
This work had no financial support. The authors appreciate the doctors who collaborated on our questionnaire: Daishi Hirano, Saitama Children’s Medical Center, Saitama, Japan; Hiroshi Kaito, Kobe University, Kobe, Japan; Tomonori Harada, Yokohama City University Medical Center, Yokohama, Japan; Hiroshi Tanaka, Hirosaki University, Hirosaki, Japan; Toshio Watanabe, Gunma University, Maebashi, Japan; Masaki Shimizu, Kanazawa University, Kanazawa, Japan; Naohiro Wada, Shizouka Children’s Hospital, Shizuoka, Japan; Osamu Uemura, Aichi Children’s Health and Medical Center, Ohbu, Japan; Masashi Nishida, Kyoto Prefectural University of Medicine, Kyoto, Japan; Kenichi Satomura, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; Rika Fujimaru, Osaka City General Hospital, Osaka Japan; Ryojiro Tanaka, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan; and Kohei Maekawa, Hyogo College of Medicine, Nishinomiya, Japan.
- 2.Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279PubMedCrossRefGoogle Scholar
- 6.Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J (2012) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27:1910–1915PubMedCrossRefGoogle Scholar
- 7.Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308–1315PubMedCrossRefGoogle Scholar
- 13.Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Furmann RR, Winter JN, Vose JM, Zelenets AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Litell NR, Talley RL, Sartot O, Green D, Major EO, lBennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840PubMedCrossRefGoogle Scholar
- 22.Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, for Arbeitsgemeinschaft für Pädiatrische Nephrologie (2008) Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 23:1483–1493PubMedCrossRefGoogle Scholar
- 26.Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117–1124PubMedCrossRefGoogle Scholar
- 31.Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118:6769–6771PubMedCrossRefGoogle Scholar